Major Depressive Disorder in Patients With Doctoral Degrees: Patient-reported Depressive Symptom Severity, Functioning, and Quality of Life Before and After Initial Treatment in the STAR*D Study

Steiner, Alexander J.; Boulos, Nathalie; Wright, Stephanie M.; Mirocha, James; Smith, Kimberly; López, Enrique; Gohar, Sherif; IsHak, Waguih William

doi:10.1097/pra.0000000000000251

Cited by 2 publications

(1 citation statement)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cognitive dysfunction in depressive disorders may be related to the decrease of dopamine function in prefrontal cortex and the relative enhancement of central 5-HT function. 11 Although the symptoms of patients with depression are relieved after intervention with antidepressants, their social function damage always continues, which is closely related to the incomplete recovery of cognitive function. 12 Therefore, increasing studies have focused on the treatment of cognitive impairment, and have shown certain advantages.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of hyperbaric oxygen combined with escitalopram in depression and its effect on cognitive function

Mi¹,

Guo

Xu³

et al. 2021

Pak J Med Sci

View full text Add to dashboard Cite

Objective: To investigate the efficacy of hyperbaric oxygen (HBO) combined with escitalopram in patients with depression and its effect on cognitive function. Methods: From 2016 to 2018, seventy patients with depression aged 18-65 years treated in Affiliated Hospital of Hebei University were selected. Seventy patients with depression meeting the diagnostic criteria of ICD-10 were selected and randomly divided into control group and observation group using a random number table, with 35 patients in each group. The control group was treated with escitalopram, while the observation group was additionally treated with HBO on this basis. The patients were assessed using the Hamilton Depression Scale (HAMD) and Montreal Cognitive Assessment Scale (MoCA) before treatment and two, four and six weeks after treatment. Results: Two weeks after treatment, HAMD score showed a statistically significant difference between the two groups (P < 0.05). No statistically significant differences were found in HAMD score between the two groups four and six weeks after treatment (P > 0.05). Four and six weeks after treatment, MoCA score presented statistically significant differences between the two groups (P < 0.05). Conclusion: Escitalopram combined with HBO in the treatment of depression presents rapid efficacy and a certain effect in improving cognitive function. doi: https://doi.org/10.12669/pjms.37.4.3993 How to cite this:Mi K, Guo Q, Xu BY, Wang M, Bi H. Efficacy of hyperbaric oxygen combined with escitalopram in depression and its effect on cognitive function. Pak J Med Sci. 2021;37(4):---------. doi: https://doi.org/10.12669/pjms.37.4.3993 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of hyperbaric oxygen combined with escitalopram in depression and its effect on cognitive function

Mi¹,

Guo

Xu³

et al. 2021

Pak J Med Sci

View full text Add to dashboard Cite

show abstract

Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression

et al. 2021

View full text Add to dashboard Cite

Aim: Estimate the cost-per-remitter with esketamine nasal spray plus an oral antidepressant (ESK + oral AD) versus oral AD plus nasal placebo (oral AD + PBO) among patients with treatment-resistant depression. Patients & methods: An Excel-based model was developed to estimate the cost-per-remitter for ESK + oral AD versus oral AD + PBO over 52 weeks from multiple US payer perspectives. Clinical end points and cost inputs were derived from clinical trials and the literature, respectively. Results: Under the base-case scenario, the cost-per-remitter for ESK + oral AD and oral AD + PBO were as follows: Commercial: US$85,808 versus US$100,198; Medicaid: US$76,236 versus US$96,067; Veteran’s Affairs: US$77,765 versus US$104,519; and Integrated Delivery Network: US$103,924 versus US$142,766. Conclusion: The findings suggest that ESK + oral AD is a cost-efficient alternative treatment for treatment-resistant depression compared with oral AD + PBO.

show abstract

Major Depressive Disorder in Patients With Doctoral Degrees: Patient-reported Depressive Symptom Severity, Functioning, and Quality of Life Before and After Initial Treatment in the STAR*D Study

Cited by 2 publications

References 73 publications

Efficacy of hyperbaric oxygen combined with escitalopram in depression and its effect on cognitive function

Efficacy of hyperbaric oxygen combined with escitalopram in depression and its effect on cognitive function

Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression

Contact Info

Product

Resources

About